Fundraising Fox
Jabez Biosciences
Cranberry Twp., US · Founded 2024 · Florida corporation
Find your way into Jabez Biosciences
Sign up to see every warm intro you have to Jabez Biosciences
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Jabez Biosciences team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Jabez Biosciences is a clinical-stage biotechnology company developing oral small-molecule cancer therapeutics under a "3-S" (seamless, scalable, synergistic) framework designed to combine with standard treatments. Its lead compound, JBZ-001, is an oral DHODH inhibitor in a Phase 1 trial for advanced solid tumors and non-Hodgkin lymphoma.
Founders & leadership
Jabez Biosciences was founded in 2024 by Robert Lewis.
RL
Robert LewisNo family relationship with Martin Lewis or Michael Lewis
BC
Brian CogleyExecutive
TJ
Tamara JovonovichNamed on SEC filing
ML
Martin LewisNo family relationship with Michael Lewis or Robert Lewis
Board
BC
Bruce CassidyBoard director
Reported raises · per SEC filings
Form D private placements$1.6M disclosed across 3 rounds · 2024
▶$31.2KraisedMar 2026 · 8 investors · BiotechnologyRule 506(b)
▶$31.2KraisedMar 2026 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael LewisPromoter
- Robert LewisExecutive Officer, Director, Promoter
- Tamara JovonovichExecutive Officer, Director, Promoter
- David MehalickPromoter
- Martin LewisDirector
- Brian CogleyExecutive Officer, Director
- Bruce CassidyDirector
- Amount sold
- $31.2K
- Minimum investment
- $100
- First sale
- Jun 2024
- Incorporated
- Corporation, Florida, 2024
- Federal exemptions
- 06b
▶$250.5KraisedOct 2025 · 3 investors · BiotechnologyRule 506(b)
▶$250.5KraisedOct 2025 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert LewisExecutive Officer, Director, Promoter
- Brian CogleyExecutive Officer, Director
- Michael LewisPromoter
- David MehalickPromoter
- Bruce CassidyDirector
- Tamara JovonovichExecutive Officer, Director, Promoter
- Martin LewisDirector
- Amount sold
- $250.5K
- Proceeds to insiders
- $350K
- First sale
- Nov 2024
- Incorporated
- Corporation, Florida, 2024
- Federal exemptions
- 06b
▶$1.3MraisedOct 2025 · 18 investors · BiotechnologyRule 506(b)
▶$1.3MraisedOct 2025 · 18 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David MehalickPromoter
- Martin LewisDirector
- Tamara JovonovichExecutive Officer, Director, Promoter
- Bruce CassidyDirector
- Brian CogleyExecutive Officer, Director
- Michael LewisPromoter
- Robert LewisExecutive Officer, Director, Promoter
- Offering amount
- $3M
- Amount sold
- $1.3M
- Minimum investment
- $500
- Proceeds to insiders
- $350K
- First sale
- Aug 2024
- Incorporated
- Corporation, Florida, 2024
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
Blaze BioscienceBlaze Bioscience is a biotechnology company developing fluorescence imaging agents that let surgeons see cancer tissue in real time during surgery. Its Tumor Paint technology and lead candidate tozuleristide (BLZ-100) aim to improve precision in cancer surgery, with current work in breast-conserving surgery.
Rayze BioRayzeBio develops radiopharmaceutical therapies for cancer treatment. The company is a subsidiary of Bristol Myers Squibb focused on advancing targeted cancer therapies to patients.
Companies working in the same space as Jabez Biosciences.
Frequently asked questions
- What does Jabez Biosciences do?
- Jabez Biosciences is a clinical-stage biotechnology company developing oral small-molecule cancer therapeutics under a "3-S" (seamless, scalable, synergistic) framework designed to combine with standard treatments. Its lead compound, JBZ-001, is an oral DHODH inhibitor in a Phase 1 trial for advanced solid tumors and non-Hodgkin lymphoma.
- Who founded Jabez Biosciences?
- Jabez Biosciences was founded by Robert Lewis in 2024.
- How much funding has Jabez Biosciences raised?
- Jabez Biosciences has disclosed $1.6M raised across 3 rounds.
- Where is Jabez Biosciences headquartered?
- Jabez Biosciences is headquartered in Cranberry Twp., US.